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e report the characterization of factor inhib-
iting activating transcription factor 4 (ATF4)–
mediated transcription (FIAT), a leucine
zipper nuclear protein. FIAT interacted with ATF4 to in-
hibit binding of ATF4 to DNA and block ATF4-mediated
transcription of the osteocalcin gene in vitro. Transgenic
mice overexpressing FIAT in osteoblasts also had reduced
osteocalcin gene expression and decreased bone mineral
density, bone volume, mineralized volume, trabecular
thickness, trabecular number, and decreased rigidity of
long bones. Mineral homeostasis, osteoclast number and
activity, and osteoblast proliferation and apoptosis were
W
 
unchanged in transgenics. Expression of osteoblastic dif-
ferentiation markers was largely unaffected and type I
collagen synthesis was unchanged. Mineral apposition
rate was reduced in transgenic mice, suggesting that the
lowered bone mass was due to a decline in osteoblast ac-
tivity. This cell-autonomous decrease in osteoblast activity
was conﬁrmed by measuring reduced alkaline phos-
phatase activity and mineralization in primary osteoblast
cultures. These results show that FIAT regulates bone mass
accrual and establish FIAT as a novel transcriptional reg-
ulator of osteoblastic function.
 
Introduction
 
Bone formation is an important physiological process that reg-
ulates skeletal growth, bone remodeling, and fracture repair.
This process is dependent on the actions of two cell types: the
bone-forming osteoblasts and the bone-resorbing osteoclasts.
The osteoblasts, of mesenchymal origin, are responsible for
bone matrix protein deposition and subsequent mineralization
in both intramembranous and endochondral bone formation
(Erlebacher et al., 1995). Osteoclasts are cells of hematopoietic
origin that are responsible for resorbing extracellular matrix
(Boyle et al., 2003). The equilibrium between bone formation
and resorption is tightly controlled, and imbalances between
the two processes lead to bone disease (Harada and Rodan,
2003; Zelzer and Olsen, 2003).
Several transcription factors have been identified as regu-
lators of osteoblastic differentiation and function (Karsenty and
Wagner, 2002), including Dlx5 (Miyama et al., 1999), Runx2/
Cbfa1 (Ducy et al., 1997; Komori et al., 1997), and Osx (Na-
kashima et al., 2002). It is likely that some of these factors
control the activity or expression of one another, forming de-
fined pathways, as suggested by the Dlx5-dependent induction
of Runx2/Cbfa1 and Osx in pluripotential cells (Lee et al.,
2003a,b). Similarly, the basic helix-loop-helix transcription
factors Twist-1 and -2 were recently shown to regulate osteo-
blast differentiation by interacting with Runx2/Cbfa1 to inhibit
its activity (Bialek et al., 2004). It is thus becoming evident that
complete understanding of the transcriptional control of osteo-
blastic differentiation and function will require further analysis
of the cross talk and interactions between particular activators
and/or repressors of gene transcription.
Several members of the basic domain-leucine zipper
(bZip) family of transcription factors have also been shown to
control osteoblast development or activity. In addition to the
AP-1 family members Fra-1 (Jochum et al., 2000) and 
 
 
 
FosB
(Sabatakos et al., 2000), the bZip factor activating transcription
factor 4 (ATF4) was also recently shown to regulate osteoblast
biology. Yang et al. (2004) showed that ATF4 is a substrate of
the RSK2 (ribosomal S6 kinase-2) kinase and regulates the
onset of osteoblast differentiation, type I collagen synthesis,
osteoblast-specific gene expression, and osteoblast terminal
differentiation. ATF4 was shown to be the osteocalcin promoter
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binding factor Osf1 (Ducy and Karsenty, 1995; Schinke and
Karsenty, 1999; Yang et al., 2004) and to regulate osteocalcin
gene transcription in a RSK2-dependent manner (Yang et al.,
2004). Mice deficient for ATF4 are runted (Tanaka et al., 1998;
Hettmann et al., 2000; Masuoka and Townes, 2002) and harbor
low bone mass (Yang et al., 2004). ATF4 can form ho-
modimers (Hai and Curran, 1991; Vallejo et al., 1993) but can
also heterodimerize with a variety of partners (Hai and Curran,
1991; Chevray and Nathans, 1992; Vallejo et al., 1993). The
dimerization partner appears to influence specificity of DNA
binding (Vallejo et al., 1993) as well as transcriptional activity
(Fawcett et al., 1999; Lim et al., 2000).
We report the cloning and characterization of factor-
inhibiting ATF4-mediated transcription (FIAT), a 66-kD leucine
zipper nuclear protein that interacts with ATF4 to inhibit bind-
ing of ATF4 to its cognate response element and blocks ATF4-
mediated transcriptional activation of the osteocalcin gene pro-
moter in vitro. Transgenic mice overexpressing FIAT under the
control of the osteoblast-specific fragment of the 
 
 
 
1(I) col-
lagen promoter were generated to study the role of FIAT in
bone-forming cells in vivo. These mice displayed an os-
teopenic phenotype accompanied by reduced osteocalcin gene
transcription, decreased bone mineral density, trabecular vol-
ume, and bone rigidity. Although osteoblast proliferation and
apoptosis were unaffected, osteoblast activity was shown to be
reduced. However, type I collagen mRNA transcription and
protein synthesis were unchanged. Thus, transgenic expression
of FIAT mimics several but not all aspects of the phenotype of
ATF4-deficient bone and suggests that FIAT inhibition of
ATF4 activity may be one of the pathways through which
FIAT affects osteoblast function.
 
Results
 
FIAT Interacts with ATF4
 
We identified FIAT in a yeast two-hybrid screen for proteins
interacting with the 
 
 
 
NAC transcriptional coactivator (Moreau
et al., 1998; Yotov et al., 1998). The interaction of the partial
FIAT cDNA with 
 
 
 
NAC was confirmed in yeast, but we could
not observe an interaction between the full-length FIAT and
the coactivator in mammalian cells (unpublished data). Thus,
the physiological relevance of the putative FIAT–
 
 
 
NAC inter-
action remains unclear and was not further pursued.
The full-length 1.8-kb FIAT cDNA translates into a 66-kD
protein that localizes to the nucleus in calvarial osteoblasts
(Fig. 1, A–C) and in ROS 17/2.8 osteoblastic cells (Majeska
et al., 1980; not depicted). The FIAT protein (accession no.
NP_060830, encoded by a gene mapping to Xp22.1, acces-
sion no. NM_018360) is predicted to form a long coiled-coil
at its COOH terminus, a structure that favors protein–protein
interactions. Moreover, computer modeling predicts the pres-
ence of putative leucine zippers within the FIAT protein (Fig.
1 A). While this manuscript was under revision, a protein
identical to FIAT was characterized on the basis of its ex-
tended COOH-terminal coiled-coil and shown to interact with
syntaxin family members (Nogami et al., 2004). Combined
with the data presented herein, it appears that FIAT can inter-
act with a variety of partners. Sorting out the physiological
relevance of all interactions will require further studies. The
FIAT mRNA is around 4.5 kb in length with an extended 3
 
 
 
-
untranslated region (unpublished data) and is ubiquitously ex-
pressed (Nogami et al., 2004).
The presence of a putative leucine zipper within the
FIAT protein sequence (Fig. 1 A) prompted us to investigate
whether FIAT could form homodimeric or heterodimeric in-
teractions. Yeast two-hybrid assays using FIAT as both the
bait and target molecules revealed that FIAT could not ho-
modimerize (Fig. 2, A and B). In a search for putative het-
erodimerization partners, we used the FIAT bait to screen
cDNA libraries from MC3T3-E1 osteoblastic cells (Sudo et
al., 1983) or primary cultures of osteoblasts (Ecarot-Charrier
et al., 1983) in the two-hybrid assay. Three independent
clones encoding the ATF4 transcription factor were isolated
from the MC3T3-E1 library, whereas two different clones
were obtained from the primary osteoblasts library, thus iden-
tifying ATF4 as a target molecule (Fig. 2, A and B). To con-
firm this interaction, reciprocal coimmunoprecipitation assays
were performed using ROS 17/2.8 osteoblastic cells. Immu-
noprecipitation of endogenous ATF4 coprecipitated endoge-
nous FIAT (Fig. 2 C, left). Reciprocally, the ATF4 protein
coimmunoprecipitated with endogenous FIAT (Fig. 2 C,
right). The use of unrelated antibodies or protein A–Seph-
arose alone confirmed the specificity of the immunoprecipita-
tion reactions (Fig. 2 C, lanes 1 and 2 on each panel). These
results demonstrate that FIAT and ATF4 interact in mamma-
lian osteoblasts.
Figure 1. FIAT protein. (A) Amino acid sequence of the human FIAT
protein. The putative leucine zipper is shaded in gray. (B) Nuclear ex-
tracts from MC3T3-E1 osteoblastic cells at confluence (lane 1) or after 6 d
of growth in the presence of ascorbic acid and  -glycerophosphate (lane 2)
were probed with the anti-FIAT peptide antibody. The arrow identifies the
66-kD FIAT protein. (C) Calvarial osteoblasts from primary cultures were
stained with the anti-FIAT antibody. The endogenous FIAT protein is de-
tected in the nucleus of the cells. 
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FIAT represses ATF4 DNA binding and 
transcriptional activity
 
ATF4 was recently characterized as an important transcrip-
tional regulator of osteoblast differentiation binding to the
OSE1 site of the osteocalcin promoter to regulate osteocalcin
gene transcription (Yang et al., 2004). ATF4 was shown to be a
substrate for the RSK2 kinase, and phosphorylation by RSK2
enhanced the transcriptional activity of ATF4 (Yang et al.,
2004). We thus examined whether or not the interaction of
FIAT with ATF4 would impact on the DNA-binding and tran-
scriptional activity of ATF4 and regulate osteocalcin gene tran-
scription in mammalian cells. In the first series of experiments,
COS-7 cells were cotransfected with a reporter construct in
which canonical ATF4 binding sites were subcloned upstream
of the thymidine kinase minimal promoter region and expres-
sion vectors for ATF4 and FIAT. The recombinant ATF4 pro-
tein strongly induced the transcription of the reporter gene,
whereas FIAT by itself was without effect (Fig. 3 A). Coex-
pression of FIAT with ATF4 significantly inhibited ATF4-
mediated transcription (Fig. 3 A). To test the impact of FIAT
on the ATF4-mediated activation of osteocalcin gene tran-
scription, osteoblastic MC3T3-E1 cells were transfected with a
reporter construct in which six copies of the OSE-1 regulatory
element from the osteocalcin gene promoter, which binds
ATF4 (Yang et al., 2004), were introduced upstream of the ad-
enovirus type 2 major late promoter fused to the luciferase re-
porter gene (vector OSE1-luc; Ducy and Karsenty, 1995). The
cells also received expression vectors for ATF4, FIAT, and
RSK2. As previously reported (Yang et al., 2004), ATF4 in-
duced the transcription of the OSE1-luc reporter, and this effect
was enhanced by RSK2 coexpression (Fig. 3 B). Increasing
amounts of FIAT suppressed the transcriptional activity of
ATF4, even in the presence of RSK2 (Fig. 3 B). A control re-
porter vector in which the OSE1 response element was mutated
did not respond to ATF4 expression (Fig. 3 B, mutOSE1).
FIAT by itself was without effect (Fig. 3 B). Similar results
were obtained when MC3T3-E1 or COS-7 cells were trans-
fected with a reporter construct under the control of the proxi-
mal 147-bp osteocalcin gene promoter (unpublished data).
These experiments demonstrated that FIAT was able to inhibit
ATF4-mediated transcription and that this inhibition was main-
tained even when ATF4 was activated by phosphorylation.
To examine the mechanisms involved, we performed
electrophoretic mobility shift assays (EMSAs) with nuclear ex-
tracts from ROS 17/2.8 osteoblastic cells and recombinant
Figure 2. FIAT interacts with ATF4. (A and B) Yeast two-hybrid protein
interaction assays. (A) Growth on two-minus selection media. (B) Growth
on three-minus selection media. (A and B) position 1, FIAT “bait”  
ATF4 “target;” position 2, negative control; position 3, positive control;
position 4, FIAT “bait”   FIAT “target” without leucine zipper; position 5,
FIAT “bait”   FIAT “target;” position 6, negative control. Note that on
three-minus selection media only yeasts at position 1 (FIAT   ATF4) and
position 3 (positive control) grow, demonstrating a positive interaction
between FIAT and ATF4. The failure of yeasts to grow at positions 4 and 5
confirm that FIAT does not homodimerize. (C) Coimmunoprecipitation.
Endogenous ATF4 was immunoprecipitated from ROS 17/2.8 osteoblas-
tic cells using an anti-ATF4 antibody, and the immunoprecipitates were
probed with the anti-FIAT antibody (left). Reciprocally, endogenous FIAT
was immunoprecipitated from ROS 17/2.8 cells using the anti-FIAT anti-
body, and the immunoprecipitates were probed with an anti-ATF4 anti-
body (right). FIAT was coimmunoprecipitated with ATF4 (left, lane 3)
and ATF4 was also coimmunoprecipitated with FIAT (right, lane 3). Pro-
tein A–Sepharose or unrelated antibodies failed to precipitate the target
proteins (lanes 1–2).
Figure 3. FIAT represses ATF4-mediated transcription and binding of
ATF4 to DNA. (A) COS-7 cells were transfected with a luciferase reporter
gene under the control of three canonical ATF4 binding sites, together
with expression vectors for human ATF4 and human FIAT. (B) MC3T3-E1
osteoblastic cells were transfected with a reporter construct in which the
luciferase gene was regulated by six copies of the wild-type (OSE1-luc) or
mutated (mut OSE1) OSE1 sequence from the mouse osteocalcin gene
promoter. Cotransfected plasmids included expression vectors for ATF4,
RSK2, or FIAT (2  signifies that twice the amount of plasmid was used).
Reporter gene activity was measured with a luminometer 24 h after trans-
fection. The activity measured in cells transfected with the reporter con-
struct and empty expression vectors was arbitrarily ascribed a value of 1.
FIAT inhibited ATF4-induced transcription from both templates (A and B),
even in the presence of an expression vector for the RSK2 kinase (B). FIAT
expression by itself does not affect transcription from the reporter tem-
plates. (C) EMSA with an OSE1 oligonucleotide probe, ROS 17/2.8 nu-
clear extract, and recombinant FIAT. The ATF4 binding complex was
identified using specific anti-ATF4 antibodies (lanes 3–5). FIAT did not
bind the probe but inhibited binding of ATF4 to the DNA. 
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FIAT protein. The probe used was a 26-bp oligonucleotide
corresponding to the OSE1 binding element and flanking nu-
cleotides from the mouse osteocalcin promoter sequence. We
observed the previously reported multiple retarded complexes
between nuclear ROS 17/2.8 proteins and the probe (Ducy and
Karsenty, 1995; Schinke and Karsenty, 1999; Yang et al.,
2004), and the ATF4 binding complex was identified using
specific inhibition of DNA binding by anti-ATF4 antibodies
(Fig. 3 C, lanes 1–5). Recombinant FIAT protein did not bind
the OSE1 probe (Fig. 3 C, lane 8), but dose-dependently inhib-
ited the binding of ATF4 to the OSE1 element (Fig. 3 C, lanes
6 and 7). Together with the data presented in Fig. 2, we inter-
pret these results to mean that FIAT heterodimerizes with nu-
clear ATF4 to prevent its binding to DNA and repress ATF4-
mediated gene transcription.
 
Reduced bone mass in mice expressing a 
FIAT transgene
 
To study the impact of FIAT on osteoblast development in
vivo, transgenic mice expressing a FIAT transgene were gener-
ated. The transgene contained the full-length 1.8-kb FIAT
cDNA fused to the 2.3-kb 
 
 
 
1(I) collagen promoter (Fig. 4 A).
This promoter fragment is known to direct transgene expres-
sion specifically in osteoblasts but not in other type I collagen-
producing cells (Rossert et al., 1995; Dacquin et al., 2002).
Tissue specificity of transgene expression was assessed by RT-
PCR, and results confirmed that the transgene was expressed
only in bone but not in other tissues (Fig. 4 B). The level of
transgene expression in bone tissue was comparable to endoge-
nous FIAT gene expression (Fig. 4 C). Histological analysis of
tibial sections obtained from 3-mo-old mice revealed an os-
teopenic phenotype in transgenic mice. The bone mass reduc-
tion was manifested as decreased number and size of trabeculae
as well as disturbed secondary centers of ossification (Fig. 4 D).
The same phenotype was observed in another strain of trans-
genic mice, confirming that it was not integration site depen-
dent (unpublished data).
The osteopenic phenotype of the FIAT transgenic mice
was further characterized using dual energy X-ray absorptiom-
etry (DEXA), histomorphometry, and biomechanical analyses.
DEXA scanning revealed a significant decrease (21%) in bone
mineral density between transgenic animals and wild-type lit-
termates (Fig. 5 A). Detailed histomorphometric measurements
demonstrated a dramatic decrease in bone volume (70%), min-
eralized bone volume (45%), trabecular thickness (38%), and
trabecular number (55%) (Fig. 5, B–E). Although the number
of osteoblasts was not statistically different between transgenic
animals and littermate controls (Fig. 5 G), measurements of
double-labeled tetracycline tibial sections (Fig. 5, J and K) re-
vealed a lowered mineral apposition rate (46%) and bone for-
mation rate (52%) in the transgenics (Fig. 5, H and I). The
same trends were observed in younger transgenic animals at 3
wk of age (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200412139/DC1). In 6-mo-old mice where bone for-
mation rates are decreased, static histomorphometric parame-
ters were similar between wild-type and transgenic littermates
(Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.
200412139/DC1).
To determine if the measured changes had any effect on
the mechanical properties of bone, femurs were subjected to
mechanical testing using the three-point bending method.
Bones from transgenic animals exhibited a 20% increase in ul-
timate displacement compared with wild-type controls (Fig. 5 F),
demonstrating that the reduced bone mineral density, lowered
Figure 4. FIAT transgenic mice. (A) Schematic representation of the Col
1-FIAT transgene. Poly A, SV40 polyadenylation signal. (B) RT-PCR assay of
transgene expression. Top panel shows specific FIAT transgene expression
using primers from the FIAT sequence and the SV40 polyadenylation se-
quence. Bottom panel shows GAPDH expression. He, heart; Ki, kidney;
Te, tendons; Br, brain; Mu, skeletal muscle; Sk, skin, Li, liver; Bo, bone.
(C) Endogenous FIAT and transgene expression in osteoblasts and bone.
RT-PCR with primers for endogenous FIAT (lanes 1 and 2) or primers spe-
cific for the transgene (lane 3). RNA was from osteoblast primary cultures
(lane 1) or calvaria. Wt, wild type; Tg, transgenic. (D) Reduced bone
mass in FIAT transgenic mice. Goldner (left) and von Kossa (right) stains of
tibial sections from FIAT transgenic mice (bottom) and wild-type littermates
(top) at 3 mo old. Note the smaller trabeculae and reduced secondary
center of ossification in transgenic animals. Bar, 500  M. 
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bone mass, and disrupted trabecular architecture resulted in a
loss of rigidity in bones of transgenic animals.
 
FIAT impairs osteoblast activity
 
A decrease in bone mass can be secondary to endocrine dys-
function or result from defects in bone resorption or formation.
Biochemical analysis of calcium, phosphate, and alkaline phos-
phatase levels in blood revealed no differences between blood
parameters in wild type and transgenics (Fig. S3, available at
http://www.jcb.org/cgi/content/full/jcb.200412139/DC1), rul-
ing out perturbations in mineral homeostasis and abnormal
turnover as the cause of the phenotype. Similarly, histomor-
phometric measurement of osteoclast number, TRAP staining,
and assessment of osteoclastic activity by collagen cross-link
assays showed similar results between the two genotypes
(Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200412139/DC1), eliminating any effect of the transgene
on the number and activity of osteoclasts.
To determine if FIAT transgene expression altered osteo-
blast proliferation and/or apoptosis, osteoblasts were stained
with PCNA to determine the rate of osteoblast proliferation, as
well as by the TUNEL assay to evaluate apoptosis. These as-
says showed that FIAT did not affect the proliferation or the
apoptotic rate of osteoblasts (Fig. 6), thus ruling out such
mechanisms as causes of the osteopenic phenotype. Histomor-
phometric data had shown an attenuated mineral apposition
rate and bone formation rate in transgenic mice (Fig. 5, H–K),
hinting at the possibility of a defect in osteoblastic activity.
When primary osteoblast cultures obtained from 7-d-old calva-
ria were analyzed for the production of alkaline phosphatase, a
marker of osteoblastic differentiation and function, a statisti-
cally significant 34% decrease was observed in transgenic mice
compared with wild type (Fig. 7 A). Similarly, alizarin red
staining of mineralized nodules formed by primary osteoblast
cultures exhibited a 70% reduction in transgenic animals com-
pared with wild type (Fig. 7 B). Primary osteoblast cultures es-
Figure 5. Histomorphometric analysis of bones from FIAT transgenic
mice compared with wild-type littermate controls at 3 mo old reveals os-
teopenia. (A–I) The number of samples is indicated within each bar. (J and K)
Double-labeling of bone surfaces with demeclocycline used to measure dy-
namic indices in H and I. Tg, transgenic; Wt, wild type. *, P   0.05; **,
P   0.01; ***, P   0.001.
Figure 6. Normal osteoblast proliferation and survival in FIAT transgenic
mice. Calvarial sections from wild-type (A and C) or transgenic (B and D)
animals were stained for PCNA (A and B) and with a DAPI nuclear stain
(C and D). Proliferation was graphed as PCNA-positive cells over DAPI-
positive cells (G). Sections from wild-type (E) and transgenic (F) littermates
were stained by TUNEL to assess apoptosis. Bars, 100  M. 
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tablished from 3-mo-old bone marrow stromal cells also dis-
played a similar pattern (Fig. 7, C and D). The decrease in
mineralization was readily evident in alizarin red–stained cul-
tures (Fig. 7, E and F).
To evaluate the impact of FIAT transgene expression on
the transcription of markers of osteoblast differentiation, RNA
levels of bone markers such as 
 
Ocn
 
, 
 
Fiat
 
, 
 
Atf4
 
, 
 
Runx2/Cbfa1
 
,
 
Osx
 
, and 
 
Bsp
 
, were quantitated by real-time RT-PCR (Fig. 8).
FIAT transgene expression inhibited 
 
Ocn
 
 transcription (Fig. 8 A),
as was observed in transient transfection assays (Fig. 3). 
 
Fiat
 
expression was elevated in the transgenics because the real-
time assay could detect transcripts from both the endogenous
and transgenic 
 
Fiat
 
 alleles. 
 
Atf4
 
, 
 
Runx2/Cbfa1
 
, and 
 
Osx
 
 gene
expression were unchanged, whereas 
 
Bsp
 
 mRNA levels were
increased. Together, these data suggest that deregulated FIAT
expression in bone cells caused an osteopenic phenotype due
to a perturbation in osteoblastic activity, without much impact
on differentiation.
ATF4 controls the transcription of genes regulating the
cellular import of amino acids (Harding et al., 2003). This was
shown to affect the production of the major secreted protein of
osteoblasts, type I collagen, and thus ATF4-deficient bones
have less type I collagen in the matrix (Yang et al., 2004). We
examined whether or not FIAT transgenic bones were similarly
affected. van Gieson staining of tibial sections from wild-type
and transgenic littermates did not reveal major changes in type
I collagen content in the matrix between the two genotypes
(Fig. 9, A and B). This finding was confirmed using quantifica-
tion of 
 
col1A1
 
 transcription by real-time RT-PCR (Fig. 9 C)
and by measuring hydroxyproline content in bone tissue (Fig.
9 D). In addition, type I collagen synthesis from primary cul-
tures of osteoblasts, in the presence or absence of nonessential
amino acids, was unaffected by the expression of the FIAT
transgene (Fig. 9 E). Thus, deregulated FIAT transgene expres-
sion mimics some, but not all, aspects of the phenotype of
ATF4-deficient bone. Nevertheless, our results show that per-
turbing FIAT expression in osteoblasts impacts on bone mass
accrual and strongly suggest that FIAT is a key determinant of
osteoblast function.
 
Discussion
 
This study uncovers FIAT as a novel leucine zipper protein that
regulates bone mass. Mice specifically expressing a FIAT
transgene in osteoblasts exhibited an osteopenic phenotype
characterized by reduced bone mineral density, bone volume,
trabecular number, and bone rigidity. Furthermore, this bone
Figure 7. Reduced activity of FIAT transgenic osteoblasts. Primary cul-
tures of osteoblasts were obtained from 6–8-d-old calvaria (A and B) or
3-mo-old bone marrow stromal cells (C and D). Cells were assayed for AP
level after 7 d or stained with alizarin red after 14 d. Number of samples
assayed is indicated within each bar. AP concentration was normalized
by protein concentration per well (A and C). Dark red mineralized nod-
ules were expressed per squared millimeter (B and D) and cells were
photographed with bright-field microscopy (E, wild type; F, transgenic).
*, P   0.05; **, P   0.01.
Figure 8. Expression of osteoblast expression markers. RNA was ex-
tracted from 3-mo-old calvaria, reverse-transcribed, and amplified with
specific TaqMan probes using real-time PCR. Relative expression between
wild-type (Wt) and transgenic (Tg) animals was calculated by the relative
standard curve method and normalized to GAPDH. *, P   0.05. 
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mass reduction was due to defective osteoblastic function
without changes in osteoblast proliferation or apoptosis. We
hypothesize that inhibition of ATF4 transcriptional activity
through heterodimer formation may be one of the molecular
mechanisms by which FIAT controls bone mass.
 
FIAT transgene expression
 
The level of expression of the FIAT transgene was compara-
ble to the expression level measured for the endogenous
FIAT allele (Fig. 3 C), leading to a slight overexpression
when quantified by real-time RT-PCR (Fig. 8 B). This trans-
lated into slightly increased FIAT protein expression in
primary osteoblasts cultured from transgenic animals (un-
published data). We propose that the slight overexpres-
sion combined with the altered transcriptional regulation of
FIAT expression conferred by the type I collagen promoter
driving the transgene jointly impact on the osteoblast to af-
fect its function.
 
FIAT regulates bone mass by affecting 
osteoblast activity
 
Bone formation is dependent on the equilibrium between bone
resorption by osteoclasts and bone formation by osteoblasts
(Karsenty and Wagner, 2002). Resorption is influenced by os-
teoclast number and activity. Our results showed that these pa-
rameters were not affected in FIAT transgenic mice. In con-
trast, bone formation is influenced by osteoblast number and
activity. The number of osteoblasts is a function of cell differ-
entiation, proliferation, and survival. We assessed differentia-
tion using a battery of markers and RNA isolated from bones,
primary calvarial cultures from newborn animals, and marrow
stromal cell cultures of adult (3-mo-old) mice. Relative expres-
sion of all markers assessed was similar irrespective of the
source of the RNA (unpublished data). Our results show no dif-
ferences between the expression of most of the markers tested,
except an increase in 
 
Bsp
 
 transcript levels and a decrease in
 
Ocn
 
 gene transcription (further discussed in the following
section). We interpret these results to mean that FIAT transgene
expression has no major effect on osteoblast differentiation.
Similarly, osteoblast proliferation and survival (apoptosis)
were unaffected by the FIAT transgene. However, dynamic
histomorphometry revealed a reduction in mineral apposition
rate and bone formation rate in transgenic mice, thus suggest-
ing that decreased osteoblastic activity was responsible for the
osteopenic phenotype. This hypothesis was confirmed by mea-
suring reduced alkaline phosphatase activity and diminished
mineralization by primary osteoblast cultures. These assays
also proved that the effect of the transgene is cell-autonomous,
as expected, because FIAT is not a secreted protein but resides
in the nucleus.
 
Molecular mechanisms of FIAT 
repression of ATF4
 
The most plausible explanation for FIAT repression of ATF4-
mediated transcription is that FIAT inhibits ATF4 by dimeriz-
ing with ATF4 through the leucine zipper region. Because
FIAT does not have a readily identifiable DNA binding do-
main, we surmised that it could prevent ATF4 from binding to
the DNA to activate transcription by forming inactive het-
erodimers. We have shown that this is the case using recombi-
nant FIAT and nuclear extracts from osteoblastic ROS 17/2.8
cells (Fig. 3 C). Further structure-function analysis with de-
leted or site-specifically mutated ATF4 and FIAT recombinant
proteins are underway to more precisely define the respective
domains that mediate interactions between the two proteins.
Other nonmutually exclusive possible mechanisms include
FIAT interference with the interaction between ATF4 and
other transcription factors or FIAT recruitment of corepressors
to the chromatin. Additional experiments will be required to
determine whether or not these mechanisms contribute to the
FIAT repressor activity.
FIAT repressed osteocalcin gene transcription in cultured
osteoblasts and in transgenic bone. The inhibition observed in
bones from FIAT transgenic animals was not as pronounced as
that measured in ATF4-deficient mice (Yang et al., 2004). The
inhibition of ATF4 transcriptional activity by FIAT would be
Figure 9. Type I collagen expression and synthesis in FIAT transgenic
mice. Femoral sections from wild-type (A) or FIAT transgenic (B) littermates
were stained with the van Gieson dye to examine type I collagen expres-
sion. Bar, 500  M. (C) Calvarial Col1A1 mRNA levels were quantified by
real-time PCR. (D) Collagen protein content in whole tibias from 3-mo-old
mice was estimated using hydroxyproline quantification. (E) Type I collagen
synthesis analysis. The histogram shows expression of [
3H]proline–labeled
 1 and  2 chains of type I collagen relative to  -actin expression (n   9 in-
dependent primary osteoblast cultures from different litters for each bar).
NEAA, nonessential amino acids; Wt, wild-type; Tg, transgenics. 
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dependent on the relative expression of FIAT and ATF4 in
transgenic animals, and it is possible that FIAT transgene ex-
pression was not high enough to block all ATF4-mediated tran-
scription of the osteocalcin gene.
It is noteworthy that the inhibition of osteocalcin gene ex-
pression observed in this study correlated with a decrease in os-
teoblast function, whereas total osteocalcin gene ablation leads
to an increase in osteoblast activity (Ducy et al., 1996). Al-
though it is possible that this difference only reflects the rela-
tive degree of inhibition of osteocalcin expression, it is more
likely that ablation of osteocalcin, a matrix constituent, leads to
a different phenotype than the perturbation of a transcriptional
regulatory cascade that, although it regulates the transcription
of osteocalcin, impacts on other transcriptional events early in
the differentiation program of the osteoblast.
Repression of ATF4-mediated transcription by FIAT is
most likely responsible for the aspects of the FIAT transgenic
mice phenotype that are a phenocopy of the ATF4-deficient an-
imals, such as reduced osteocalcin transcription, low bone
mass, and reduced osteoblast activity (Yang et al., 2004). Sev-
eral differences exist between the two strains, however. As pre-
viously mentioned, transgenic FIAT expression did not have a
major impact on the onset or extent of osteoblast differentia-
tion. FIAT also did not affect type I collagen synthesis (Fig. 9).
Type I collagen is the most abundant protein produced by os-
teoblasts and constitutes the majority of the mineralization
scaffold in bone. ATF4 regulates amino acid import in several
cell types (Harding et al., 2003), and the reduction in type I col-
lagen synthesis in ATF4-deficient mice was associated with
this function of the ATF4 protein (Yang et al., 2004). It re-
mains possible that FIAT does not modulate this activity of the
ATF4 protein and thus would not impact on type I collagen
synthesis. Alternatively, our results could be due to the rela-
tively low level of FIAT overexpression achieved in the trans-
genics. Additional studies (including structure-function analy-
sis of the FIAT–ATF4 interaction and its impact on the
transcription of other ATF4 target genes besides osteocalcin,
FIAT RNA knock-down, or FIAT ablation by gene targeting)
will be required to elucidate this point.
It also remains a formal possibility that FIAT may disturb
bone formation by other mechanisms in addition to suppressing
ATF4 transcriptional activity. FIAT could heterodimerize with
additional bZip transcription factors, such as Fra-1 or 
 
 
 
FosB,
that have been shown to regulate bone mass accrual (Jochum et
al., 2000; Sabatakos et al., 2000). Alternatively, FIAT could se-
quester dimerization partners away from bone mass–controlling
bZip factors. A likely candidate remains c-Jun, a well established
dimerization partner of Fos family members (Hartl et al., 2003).
At any rate, our results show that the transcriptional con-
trol of osteoblast activity is a tightly regulated phenomenon and
confirm that protein–protein interactions play a critical role in
the precise regulation of gene expression in bone-forming cells.
 
Materials and methods
 
Yeast two-hybrid
 
cDNA libraries from osteoblastic MC3T3-E1 cells or cultured primary os-
teoblasts were prepared in the pAD-GAL4 vector (Stratagene) using the
HybriZAP Two-Hybrid cDNA Gigapack cloning kit and following the man-
ufacturer’s instruction. The 
 
 
 
Nac or FIAT baits were prepared by subclon-
ing the respective cDNAs into the GAL4-DBD expression plasmid (Strat-
agene). The screen was performed according to the manufacturer’s
protocols, and interaction between molecules was identified in yeast that
were grown in selective medium lacking three essential amino acids: TRP,
LEU, and URA.
 
Western blotting, immunocytochemistry, and coimmunoprecipitation
 
A peptide corresponding to FIAT residues 111–125 was synthesized, cou-
pled to ovalbumin, and used to raise rabbit polyclonal antibodies follow-
ing standard protocols. The polyclonal antisera (1:1,500 dilution) was
used to probe immunoblots of nuclear extracts from osteoblastic MC3T3-
E1 cells. Anti–rabbit antibodies conjugated with HRP (1:25,000 dilution)
were used as secondary antibodies and detected by ECL Western blotting
detection reagents (Amersham Biosciences). The antibody was also used
for indirect immunofluorescence. Primary cultures of osteoblasts were ob-
tained from 6–8-d-old calvaria. In brief, calvaria were minced and digested
sequentially (5 
 
 
 
 10 min) with 
 
 
 
MEM containing 0.2% collagenase D
(Roche) and 0.1% hyaluronidase (Roche). Fractions 3 to 5 were collected
and plated in a 6-well plate with 
 
 
 
MEM containing 10% FBS, 2%
Glutamax, 1% penicillin, 1% streptomycin, and 1% Fungizone (Invitrogen).
Cells attached for 7 d and were cultured in the presence of 10
 
 
 
8 
 
M dexa-
methasone (Porter et al., 2003; Yang et al., 2003). The primary osteo-
blasts were fixed in 4% PFA and permeabilized with 0.2% Triton X-100.
After blocking with 1% blocking reagent (Roche) supplemented with 0.2%
Tween-20, the cells were incubated with the anti-FIAT antibody (1:200).
The cells were incubated for 1–2 h at RT with a rhodamine-conjugated
anti–rabbit IgG secondary antibody (dilution 1:500) to detect endogenous
FIAT protein. Coverslips were mounted in Vectashield (with DAPI) mount-
ing medium (Vector Laboratories).
For coimmunoprecipitation, 100–200 
 
 
 
g of nuclear proteins from
ROS 17/2.8 osteoblastic cells in buffer D (20 mM Hepes-KOH, pH 7.9,
25% glycerol, 150 mM NaCl, 1.5 mM MgCl
 
2
 
, and 0.2 mM EDTA with in-
hibitors of proteases: 5 
 
 
 
g/ml leupeptin, aprotinin, pepstatin A, and 1
mM PMSF) were precleared with 50 
 
 
 
l of protein A–Sepharose slurry (Am-
ersham Biosciences) for 1 h at 4
 
 
 
C with gentle rocking. After centrifuga-
tion, the cleared extract was incubated overnight at 4
 
 
 
C with gentle rock-
ing, with or without 1–2 
 
 
 
g of specific or unrelated antibody, and with 50
 
 
 
l of protein A–Sepharose slurry. The precipitates were washed with hy-
potonic buffer (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCl
 
2
 
, 10 mM KCl,
and protease inhibitors as above) and resuspended in 25 
 
 
 
l of PBS. A
10-
 
 
 
l aliquot was mixed with SDS-sample buffer, separated on 12% SDS-
PAGE, and transferred to PVDF, and the blots were probed with anti-ATF4
antibodies (Santa Cruz Biotechnology, Inc.) or anti-FIAT antiserum, and
then with anti–rabbit secondary antibody conjugated to HRP. Proteins
were detected by chemifluorescence with ECL Plus Western blotting detec-
tion reagents (Amersham Biosciences).
 
Transfection experiments
 
COS-7 or MC3T3-E1 cells were plated at 1.5 
 
 
 
 10
 
5
 
 cells/well in a 6-well
plate and transfected with 400 ng of the ATF sites reporter (provided by
T. Hai, Ohio State University, Columbus, OH; Liang and Hai, 1997) or
1 
 
 
 
g of the OSE1-luc reporter (Ducy and Karsenty, 1995), 400 ng of
pCMV5ATF4, 25 ng of pK3HRSK2 (all gifts of G. Karsenty, Baylor Col-
lege of Medicine, Houston, TX), 400 or 800 ng of pcDNA3.1/V5-HIS-
TOPOFIAT, 50 ng of pSV
 
6
 
TKCAT (obtained from R. Tjian, University of
California, Berkeley, Berkeley, CA), and a varying amount of pBluescript
reporter vectors using Lipofectamine (Invitrogen) reagents according to the
manufacturer’s instructions. Luciferase assay and chloramphenicol acetyl-
transferase ELISA (Roche) were performed 24 h after transfection follow-
ing the manufacturer’s protocol. Data represent ratios of luciferase/
chloramphenicol transferase activity and values are the means of three in-
dependent transfection experiments performed in duplicate.
 
EMSAs
 
Complementary oligonucleotides corresponding to the OSE1 binding site
within the murine osteocalcin proximal promoter region (5
 
 
 
-CCTGCTC-
CTCCTGCTTACATCAGAGA-3
 
 
 
) were synthesized with an overhang,
annealed, and labeled with [
 
32
 
P]-labeled dNTPs by Klenow fill-in using
standard protocols (Ausubel et al., 1993).
The recombinant FIAT protein was purified using NEB’s IMPACT sys-
tem as described previously (Quelo et al., 2002). ROS17/2.8 nuclear ex-
tracts were prepared following the technique of Andrews and Faller (1991).
Recombinant protein (300 or 600 ng) or nuclear extracts (10  g)
were incubated for 30 min at 4 C in 20  l of binding buffer (20 mMFIAT DECREASES BONE FORMATION • YU ET AL. 599
Hepes, pH 7.9, 60 mM KCl, 1 mM DTT, 1 mM EDTA, 100 ng of polydI-
dC, and 12% glycerol). Labeled probe (10,000 dpm) was added to the
binding reaction mixture. For supershift assays, anti-ATF4 or unrelated an-
tibody (2–4  g; Santa Cruz Biotechnology, Inc.) was added to the bind-
ing reaction for 30 min before the addition of the labeled probe. The
bound mixtures were size-fractionated on a nondenaturing 5% polyacryl-
amide gel at 160 V for 100 min in 0.5  Tris-borate-EDTA buffer. The gel
was subsequently dried and autoradiographed.
Generation of FIAT transgenic mice
FIAT transgenic mice were generated using a pCI (Promega)-based vector
containing the osteoblast-specific 2.3-kb  1(I)collagen promoter (a gift
from B. de Crombrughe, MD Anderson Cancer Center, Houston, TX; Ros-
sert et al., 1995), an SV40 small intron, the 1.8-kb full-length FIAT cDNA,
and the 240-bp SV40 polyadenylation signal. The linearized construct
was injected at 1  g/ml into fertilized eggs using standard methodology
(Hogan et al., 1994). Founder animals were detected by Southern blot.
Tissue specificity of transgene expression was examined by RT-PCR. The
transgenic line was maintained by crossing with wild-type C57BL/6 mice
and genotyped by PCR using FIAT primers (5 -ATCCATCAAAGCGCCAT-
CAAAGCG-3  and 5 -ACAAATAAAGCAATAGCATCACAA-3 ) and
Gapdh  (glyceraldehydes-3-phosphate dehydrogenase) primers (5 -CAC-
CATGGAGAAGGCCGGG-3  and 5 -GACGGACACATTGGGGGTAG-3 ).
Mice were killed and analyzed at 3 mo old. Demeclocycline (Sigma-
Aldrich) was injected at 30 ng/g of mice twice at 5-d intervals before sac-
rifice. At least 10 animals of each genotype were used for all experiments,
and statistical significance was assessed by t test. Error bars represent
SEM. All animal experimentation was approved by the Institutional Animal
Care and Use Committee.
RT-PCR
RNA from primary osteoblasts or 3-mo-old calvaria was extracted with
TRIzol (Invitrogen) following the manufacturer’s instructions. 5  g of RNA
were reverse transcribed into cDNA with 500 ng of random primers, 25 mM
dNTPs, 5  l of 0.1 M DTT, 10  l 5  first strand buffer, 3.5  l RNAguard
(Roche), and 2  l M-MLV reverse transcriptase (Promega). Endogenous or
transgenic Fiat and Gapdh genes were amplified by PCR using the prim-
ers described in the section Generation of FIAT transgenic mice.
Morphological analysis
Bone mineral density was determined by DEXA and data were analyzed
by Lunar PIXImus software before mice were killed. Bone samples were
fixed in 4% PFA, either embedded in methyl methacrylate, or decalcified
and embedded in paraffin for future studies. For histological analysis,
methyl methacrylate–embedded tibiae sections (5  m) were stained with
Goldner, Toluidine blue, and von Kossa reagents. Histomorphometric
measurements were performed using Nova Prime software (BioQuant Im-
age Analysis Corporation). Femurs preserved in PBS were first scanned
with microcomputerized tomography (MicroCT) before performing three-
point bending test at the Centre for Bone and Periodontal Research of
McGill University.
Osteoblast proliferation and apoptotic experiments
Demineralized paraffin-embedded calvarial sections (6  m) were used for
all immunohistochemical experiments. Proliferation rate of osteoblasts was
determined by the Proliferating Cell Nuclear Antigen (PCNA) Staining Kit
(Zymed Laboratories) following the manufacturer’s instructions. Sections
were counterstained with DAPI (Vector Laboratories), and values were ex-
pressed as the number of proliferating osteoblasts over the number of
DAPI-positive cells. Apoptotic rate of osteoblasts was assessed using the
TUNEL-based in situ Cell Death Detection Kit, POD (Roche), followed by
staining with DAB substrate (Vector Laboratories). Experiments were per-
formed according to the manufacturers’ instructions except that sections
were unmasked with 0.1% trypsin and counterstained with methyl green.
Colorimetric determination of AP and alizarin red staining
Primary cultures of osteoblasts were obtained from 6–8-d-old calvaria or
3-mo-old bone marrow stromal cells. Osteoblasts from calvaria were pre-
pared as described in the section Western blotting, immunocytochemistry,
and coimmunoprecipitation. For osteoblasts from bone marrow stromal
cells, epiphysis from both ends of femurs were cut off. Bone marrow cells
were flushed out with a 22-gauge needle with the previous medium, resus-
pended, and plated at 10
6 cells per well in a 6-well plate. After cell at-
tachment on day 4, medium was changed every 3 d, provided with ad-
ditional 50  g/ml ascorbic acid (Franceschi and Iyer, 1992), 10 mM
 -glycerophosphate (Quarles et al., 1992), and 10
 8 M dexamethasone
(Porter et al., 2003; Yang et al., 2003). Cells were assayed for AP level
after 7 d or stained with alizarin red after 14 d. Cells were trypsinized
with 0.05% trypsin-EDTA and plated at 5   10
4 cells/well in two 12-well
plates separately. For colorimetric determination of AP level, cells were
fixed by 4% PFA and lysed. 1 mg/ml 4-nitrophenyl phosphate (Sigma-
Aldrich) was added to each well and incubated for 30 min before read-
ing at 405 nm. Protein concentration in cell lysate was determined by the
Bradford assay. AP concentration was normalized by protein concentra-
tion per well. For alizarin red staining, cells were fixed with 4% PFA and
stained with 0.5% alizarin red (Sigma-Aldrich) at pH 5.0. Dark red miner-
alized nodules were expressed per squared millimeter and cells were pho-
tographed with bright-field microscopy.
Real-time RT-PCR
RNA from 3-mo-old calvaria was extracted with TRIzol (Invitrogen) follow-
ing the manufacturer’s instructions. 5  g of RNA were reverse transcribed
into cDNA using the High Capacity cDNA Archive kit as per the manufac-
turer’s recommendations (Applied Biosystems). Real-time PCR amplification
was performed on a 7700 instrument (Applied Biosystems) using specific
TaqMan assays for Osteocalcin (OCN), Fiat, Atf4, Runx2/Cbfa1, Osterix
(Osx), Bone Sialoprotein (Bsp), or type I collagen (col1A1) and the Taq-
Man Universal PCR Master Mix (Applied Biosystems). Expression level of
each mRNA was quantified by the relative standard curve method (User
bulletin #2; ABI Prism 7700 Sequence Detection System) and normalized
to Gapdh levels.
van Gieson staining
The van Gieson stain was prepared by dissolving 0.5 g of Sirius red F3B
(Direct Red; Sigma-Aldrich) in 500 ml of saturated picric acid in water.
Deparaffinized, rehydrated sections were stained for 1 h in van Gieson
stain, rinsed in 0.5% acetic acid, dehydrated in three changes of 100%
ethanol, cleared in xylene, and mounted.
Analysis of collagen content and synthesis
The collagen content of bones was analyzed as hydroxyproline content by
the method of Burleigh et al. (1974). In brief, demineralized tibial bone
(typically 2–5 mg) was hydrolyzed in 6 M HCl (40  l/mg) at 110 C for
20 h. A 35- l aliquot of the digest was neutralized by the addition of 35  l
of 6 M NaOH, and the solution was then diluted by the addition of 1 ml
of water and clarified by the addition of activated charcoal resin. After
centrifugation, a 20- l aliquot of the supernatant was analyzed for hy-
droxyproline content after treatment with chloramine T reagent and color
development with dimethylaminobenzaldehyde. Absorbance was mea-
sured at 560 nm and compared with hydroxyproline standards (0.1–5  g
in 20  l). Collagen synthesis by osteoblasts was determined following the
technique described by Yang et al. (2004) with the following modifica-
tions: wild-type and FIAT transgenic primary osteoblasts were labeled for
12 h with 50  Ci/ml of [
3H]proline (Amersham Biosciences) in high-glucose
DME (GIBCO BRL) supplemented with 2% dialyzed FBS, 2 mM Glutamax
(GIBCO BRL), and 55  M  -mercaptoethanol in the presence or absence
of nonessential amino acids mix. Cells were homogenized in 500  l of
PBS with protease inhibitors (5  g/ml leupeptin, aprotinin, pepstatin A,
and 1 mM PMSF). 50  l were used for protein quantification using the
Bradford assay. A 200- l additional fraction served for  -actin determina-
tion by Western blotting. The remaining 250  l of cell homogenate were
digested to collagen with 50  g/ml of pepsin, precipitated, and resolved
by SDS-PAGE on a 7% gel with 2 M urea as described previously (Yang et
al., 2004). The wet gels were soaked in amplifying reagent (Amplify; Am-
ersham Biosciences), dried, and exposed to Hyperfilm MP (Amersham Bio-
sciences). The intensity of the signal was quantified using the GeneTools
software (v. 2.11.03; Syngene USA) and normalized to  -actin expression.
Image acquisition
Micrographs in Figs. 1, 4, 5, 6, and 9 and in Fig. S4 were visualized on
a microscope (model DM-R; Leica) with Fluotar objectives (magnification/
NA: 5 /0.15; 10 /0.30; 20 /0.50; 40 /0.75). The micrographs in
Fig. 7 were visualized on an inverted microscope (model DM-IL; Leica).
For Fig. 7, images were acquired on film (160 ASA; Tungsten) with a
camera (model MPS52; Wild Leitz) connected to a photoautomat (model
MPS46; Wild Leitz), and the slides were digitalized with a scanner (model
Super Coolscan 4000 ED; Nikon). For Fig. 2, the plates were photo-
graphed using a digital camera (model Coolpix 995; Nikon). All other im-
ages were acquired using a digital camera (model DC300F; Leica) with
the IM50 image management software (Leica).
Image processing included whole image channel filtering to remove
noise and whole image adjustment of brightness, contrast, color balance,JCB • VOLUME 169 • NUMBER 4 • 2005 600
and sharpening using Adobe Photoshop v. 5.5. Photoshop images were
then flattened and imported into Adobe Illustrator v. 8.0 to build the final
montages. A shadow was removed from the top center area of Fig. 7 F
using the Photoshop cloning tool.
Online supplemental material
Four supplementary figures showing histomorphometric analysis of bones
from FIAT transgenic mice and wild-type littermate controls at 3 wk (Fig. S1)
and 6 mo (Fig. S2) old, blood biochemistry (Fig. S3), and osteoclast num-
ber, differentiation, and activity (Fig. S4) are available at http://
www.jcb.org/cgi/content/full/jcb.200412139/DC1.
We thank Mia Esser and Louise Marineau for expert technical help with the
transgenic animals, Sabrina Pacheco for genotyping the mice, and Alice Ara-
bian for breeding colony management and technical help. Mark Lepik pre-
pared the figures. Dr. Benoit de Crombrughe, Dr. Tsonwin Hai, and Dr. Rob-
ert Tjian provided plasmids. We are grateful to McGill University and the
Genome Quebec Innovation Centre for allowing repeated usage of the real-
time PCR instrument. Bone densitometry was performed at the Centre for Bone
and Periodontal Research of McGill University. R. St-Arnaud is indebted to Dr.
Gérard Karsenty and to Xiangli Yang for providing plasmids and sharing ex-
perimental protocols and unpublished data.
This work was supported by a grant from the Shriners of North America.
Submitted: 21 December 2004
Accepted: 13 April 2005
References
Andrews, N.C., and D.V. Faller. 1991. A rapid micropreparation technique for
extraction of DNA-binding proteins from limiting numbers of mamma-
lian cells. Nucleic Acids Res. 19:2499.
Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A.
Smith, and K. Struhl. 1993. Enzymatic manipulation of DNA and RNA.
In Current Protocols in Molecular Biology. John Wiley and Sons, NY.
3.5.7–3.5.9.
Bialek, P., B. Kern, X. Yang, M. Schrock, D. Sosic, N. Hong, H. Wu, K. Yu,
D.M. Ornitz, E.N. Olson, et al. 2004. A twist code determines the onset
of osteoblast differentiation. Dev. Cell. 6:423–435.
Boyle, W.J., W.S. Simonet, and D.L. Lacey. 2003. Osteoclast differentiation
and activation. Nature. 423:337–342.
Burleigh, M.C., A.J. Barrett, and G.S. Lazarus. 1974. Cathepsin B1. A lysoso-
mal enzyme that degrades native collagen. Biochem. J. 137:387–398.
Chevray, P.M., and D. Nathans. 1992. Protein interaction cloning in yeast: iden-
tification of mammalian proteins that react with the leucine zipper of
Jun. Proc. Natl. Acad. Sci. USA. 89:5789–5793.
Dacquin, R., M. Starbuck, T. Schinke, and G. Karsenty. 2002. Mouse alpha1(I)-
collagen promoter is the best known promoter to drive efficient Cre re-
combinase expression in osteoblast. Dev. Dyn. 224:245–251.
Ducy, P., and G. Karsenty. 1995. Two distinct osteoblast-specific cis-acting ele-
ments control expression of a mouse osteocalcin gene. Mol. Cell. Biol.
15:1858–1869.
Ducy, P., C. Desbois, B. Boyce, G. Pinero, B. Story, C. Dunstan, E. Smith, J.
Bonadio, S. Goldstein, C. Gundberg, et al. 1996. Increased bone forma-
tion in osteocalcin-deficient mice. Nature. 382:448–452.
Ducy, P., R. Zhang, V. Geoffroy, A.L. Ridall, and G. Karsenty. 1997. Osf2/Cbfa1:
a transcriptional activator of osteoblast differentiation. Cell. 89:747–754.
Ecarot-Charrier, B., F.H. Glorieux, M. van der Rest, and G. Pereira. 1983. Os-
teoblasts isolated from mouse calvaria initiate matrix mineralization in
culture. J. Cell Biol. 96:639–643.
Erlebacher, A., E.H. Filvaroff, S.E. Gitelman, and R. Derynck. 1995. Toward a
molecular understanding of skeletal development. Cell. 80:371–378.
Fawcett, T.W., J.L. Martindale, K.Z. Guyton, T. Hai, and N.J. Holbrook. 1999.
Complexes containing activating transcription factor (ATF)/cAMP-
responsive-element-binding protein (CREB) interact with the CCAAT/
enhancer-binding protein (C/EBP)-ATF composite site to regulate
Gadd153 expression during the stress response. Biochem. J. 339:135–141.
Franceschi, R.T., and B.S. Iyer. 1992. Relationship between collagen synthesis
and expression of the osteoblast phenotype in MC3T3-E1 cells. J. Bone
Miner. Res. 7:235–246.
Hai, T., and T. Curran. 1991. Cross-family dimerization of transcription factors
Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl.
Acad. Sci. USA. 88:3720–3724.
Harada, S., and G.A. Rodan. 2003. Control of osteoblast function and regulation
of bone mass. Nature. 423:349–355.
Harding, H.P., Y. Zhang, H. Zeng, I. Novoa, P.D. Lu, M. Calfon, N. Sadri, C.
Yun, B. Popko, R. Paules, et al. 2003. An integrated stress response reg-
ulates amino acid metabolism and resistance to oxidative stress. Mol.
Cell. 11:619–633.
Hartl, M., A.G. Bader, and K. Bister. 2003. Molecular targets of the oncogenic
transcription factor jun. Curr. Cancer Drug Targets. 3:41–55.
Hettmann, T., K. Barton, and J.M. Leiden. 2000. Microphthalmia due to p53-
mediated apoptosis of anterior lens epithelial cells in mice lacking the
CREB-2 transcription factor. Dev. Biol. 222:110–123.
Hogan, B., R. Beddington, F. Costantini, and E. Lacy. 1994. Manipulating the
Mouse Embryo. A Laboratory Manual, second edition. Cold Spring Har-
bor Laboratory Press, Cold Spring Harbor, NY. 497 pp.
Jochum, W., J.P. David, C. Elliott, A. Wutz, H. Plenk Jr., K. Matsuo, and E.F.
Wagner. 2000. Increased bone formation and osteosclerosis in mice
overexpressing the transcription factor Fra-1. Nat. Med. 6:980–984.
Karsenty, G., and E.F. Wagner. 2002. Reaching a genetic and molecular under-
standing of skeletal development. Dev. Cell. 2:389–406.
Komori, T., H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y.
Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, et al. 1997. Targeted dis-
ruption of Cbfa1 results in a complete lack of bone formation owing to
maturational arrest of osteoblasts. Cell. 89:755–764.
Lee, M.H., Y.J. Kim, H.J. Kim, H.D. Park, A.R. Kang, H.M. Kyung, J.H. Sung,
J.M. Wozney, and H.M. Ryoo. 2003a. BMP-2-induced Runx2 expres-
sion is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced
osteoblast differentiation by suppression of Dlx5 expression. J. Biol.
Chem. 278:34387–34394.
Lee, M.H., T.G. Kwon, H.S. Park, J.M. Wozney, and H.M. Ryoo. 2003b. BMP-
2-induced Osterix expression is mediated by Dlx5 but is independent of
Runx2. Biochem. Biophys. Res. Commun. 309:689–694.
Liang, G., and T. Hai. 1997. Characterization of human activating transcription
factor 4, a transcriptional activator that interacts with multiple domains
of cAMP-responsive element-binding protein (CREB)-binding protein.
J. Biol. Chem. 272:24088–24095.
Lim, C., H. Sohn, Y. Gwack, and J. Choe. 2000. Latency-associated nuclear an-
tigen of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8)
binds ATF4/CREB2 and inhibits its transcriptional activation activity.
J. Gen. Virol. 81:2645–2652.
Majeska, R.J., S.B. Rodan, and G.A. Rodan. 1980. Parathyroid hormone-
responsive clonal cell lines from rat osteosarcoma. Endocrinology. 107:
1494–1503.
Masuoka, H.C., and T.M. Townes. 2002. Targeted disruption of the activating
transcription factor 4 gene results in severe fetal anemia in mice. Blood.
99:736–745.
Miyama, K., G. Yamada, T.S. Yamamoto, C. Takagi, K. Miyado, M. Sakai, N.
Ueno, and H. Shibuya. 1999. A BMP-inducible gene, dlx5, regulates os-
teoblast differentiation and mesoderm induction. Dev. Biol. 208:123–133.
Moreau, A., W.V. Yotov, F.H. Glorieux, and R. St-Arnaud. 1998. Bone-specific
expression of the alpha chain of the nascent polypeptide-associated com-
plex, a coactivator potentiating c-Jun-mediated transcription. Mol. Cell.
Biol. 18:1312–1321.
Nakashima, K., X. Zhou, G. Kunkel, Z. Zhang, J.M. Deng, R.R. Behringer, and
B. de Crombrugghe. 2002. The novel zinc finger-containing transcription
factor osterix is required for osteoblast differentiation and bone formation.
Cell. 108:17–29.
Nogami, S., S. Satoh, S. Tanaka-Nakadate, K. Yoshida, M. Nakano, A. Terano,
and H. Shirataki. 2004. Identification and characterization of taxilin iso-
forms. Biochem. Biophys. Res. Commun. 319:936–943.
Porter, R.M., W.R. Huckle, and A.S. Goldstein. 2003. Effect of dexamethasone
withdrawal on osteoblastic differentiation of bone marrow stromal cells.
J. Cell. Biochem. 90:13–22.
Quarles, L.D., D.A. Yohay, L.W. Lever, R. Caton, and R.J. Wenstrup. 1992.
Distinct proliferative and differentiated stages of murine MC3T3-E1
cells in culture: an in vitro model of osteoblast development. J. Bone
Miner. Res. 7:683–692.
Quelo, I., M. Hurtubise, and R. St-Arnaud. 2002. alphaNAC requires an inter-
action with c-Jun to exert its transcriptional coactivation. Gene Expr.
10:255–262.
Rossert, J., H. Eberspaecher, and B. de Crombrugghe. 1995. Separate cis-acting
DNA elements of the mouse pro- 1(I) collagen promoter direct expres-
sion of reporter genes to different type I collagen-producing cells in
transgenic mice. J. Cell Biol. 129:1421–1432.
Sabatakos, G., N.A. Sims, J. Chen, K. Aoki, M.B. Kelz, M. Amling, Y. Bouali,
K. Mukhopadhyay, K. Ford, E.J. Nestler, and R. Baron. 2000. Overex-
pression of DeltaFosB transcription factor(s) increases bone formation
and inhibits adipogenesis. Nat. Med. 6:985–990.
Schinke, T., and G. Karsenty. 1999. Characterization of Osf1, an osteoblast-spe-
cific transcription factor binding to a critical cis-acting element in theFIAT DECREASES BONE FORMATION • YU ET AL. 601
mouse osteocalcin promoters. J. Biol. Chem. 274:30182–30189.
Sudo, H., H.A. Kodama, Y. Amagai, S. Yamamoto, and S. Kasai. 1983. In vitro
differentiation and calcification in a new clonal osteogenic cell line de-
rived from newborn mouse calvaria. J. Cell Biol. 96:191–198.
Tanaka, T., T. Tsujimura, K. Takeda, A. Sugihara, A. Maekawa, N. Terada, N.
Yoshida, and S. Akira. 1998. Targeted disruption of ATF4 discloses its
essential role in the formation of eye lens fibres. Genes Cells. 3:801–810.
Vallejo, M., D. Ron, C.P. Miller, and J.F. Habener. 1993. C/ATF, a member of
the activating transcription factor family of DNA-binding proteins, dimer-
izes with CAAT/enhancer-binding proteins and directs their binding to
cAMP response elements. Proc. Natl. Acad. Sci. USA. 90:4679–4683.
Yang, L., T. Tao, X. Wang, N. Du, W. Chen, S. Tao, Z. Wang, and L. Wu. 2003.
Effects of dexamethasone on proliferation, differentiation and apoptosis of
adult human osteoblasts in vitro. Chin. Med. J. (Engl.). 116:1357–1360.
Yang, X., K. Matsuda, P. Bialek, S. Jacquot, H.C. Masuoka, T. Schinke, L. Li,
S. Brancorsini, P. Sassone-Corsi, T.M. Townes, et al. 2004. ATF4 is a
substrate of RSK2 and an essential regulator of osteoblast biology; im-
plication for Coffin-Lowry Syndrome. Cell. 117:387–398.
Yotov, W.V., A. Moreau, and R. St-Arnaud. 1998. The alpha chain of the na-
scent polypeptide-associated complex functions as a transcriptional co-
activator. Mol. Cell. Biol. 18:1303–1311.
Zelzer, E., and B.R. Olsen. 2003. The genetic basis for skeletal diseases. Nature.
423:343–348.